GAA
MGX icon

Green Alpha Advisors’s Metagenomi Therapeutics MGX Stock Holding History

Green Alpha Advisors’s Portfolio MGX Stock Details MGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-14,252
Closed -$33.8K – 121
2025
Q3 		$33.8K Sell
14,252
-4,206
-23% -$8.53K 0.03% 100
2025
Q2 		$27.3K Sell
18,458
-5,571
-23% -$8.72K 0.03% 108
2025
Q1 		$32.7K Sell
24,029
-201
-0.8% -$479 0.03% 111
2024
Q4 		$87.5K Sell
24,230
-7,463
-24% -$18K 0.07% 145
2024
Q3 		$68.8K Buy
+31,693
New +$110K 0.05% 139

Other funds holding MGX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Green Alpha Advisors's MGX Position: Q4 2025 in Review

Green Alpha Advisors sold out of Metagenomi Therapeutics (MGX) in Q4 2025, closing a stake of 14,252 shares — an estimated $33.8K sold.

Green Alpha Advisors first reported a position in MGX in Q3 2024 and held it in 5 quarters. The position peaked at $87.5K in Q4 2024. 56 funds tracked by Wall St. Rank hold MGX as of Q4 2025.

  • Green Alpha Advisors reported no remaining Metagenomi Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Green Alpha Advisors sold 14,252 Metagenomi Therapeutics shares in Q4 2025, an estimated $33.8K.
  • Green Alpha Advisors first reported a position in Metagenomi Therapeutics in Q3 2024 and held it in 5 quarters.
  • Green Alpha Advisors's Metagenomi Therapeutics position peaked at $87.5K in Q4 2024.
  • 56 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q4 2025.

Based on Green Alpha Advisors's 13F filing for Q4 2025, filed 7 Jan 2026.